알라리티 테라퓨틱스(ALLR)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.37 (+0.74%), 시가총액 $0.02B, 52주 범위 $0.80 ~ $1.97.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemot
알라리티 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
알라리티 테라퓨틱스의 현재 주가는 $1.37 (+0.74%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
알라리티 테라퓨틱스의 시가총액은 약 $0.02B입니다.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United